Can Wegovy Be Stopped Abruptly, or Does It Need Tapering?

What the STEP programme found when participants stopped semaglutide

The clearest evidence comes from the STEP 4 withdrawal trial. Participants who had already lost weight over 20 weeks on semaglutide 2.4mg were then randomised either to continue or to switch to placebo. Those who switched regained around two-thirds of their lost weight by week 68. Appetite, hunger scores and waist circumference all moved back toward baseline relatively quickly after the last injection.

This matters because it reframes what stopping Wegovy actually means. It is not a question of physical dependency or withdrawal in a pharmacological sense. Semaglutide's half-life is roughly one week, so it clears the body within about five weeks of the final dose. What returns in that window is the underlying biology, the appetite signals that the medicine had been modulating. Understanding why weight loss stops or reverses on Wegovy helps put this in context: the medicine manages a condition; it does not cure it. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction at 68 weeks with semaglutide 2.4mg, and STEP 4 showed much of that is lost again after stopping.

NICE's appraisal of semaglutide for weight management (TA875) specifically recommends it for use for a maximum of two years within a specialist weight management service, and includes a review point at six months if less than 5% weight loss has occurred. That framework assumes a planned ending, not an abrupt one.

Is there any risk in stopping Wegovy suddenly?

There is no recognised discontinuation syndrome with semaglutide. You will not experience rebound hypertension, seizures or the kind of acute physical risks associated with abruptly stopping certain cardiovascular or neurological medicines. In that narrow sense, stopping suddenly is not a clinical emergency.

What does happen is more gradual. Gastric emptying, which semaglutide slows, returns to its normal rate. The sense of fullness after meals diminishes. Hunger tends to increase noticeably within the first one to two weeks. For some people this feels quite sudden; others describe it as a slow drift. If you have been on treatment long enough to have reduced your food intake significantly, returning appetite without preparation can lead to rapid calorie rebound.

The practical risks are therefore largely behavioural and metabolic rather than acute. People who stop without a plan are less likely to have the lifestyle scaffolding in place to hold their progress. What to expect after stopping Wegovy covers this transition in more detail, including the timeline of appetite returning and steps that can support weight maintenance.

One sensible parallel: if you have been injecting weekly on a Monday morning before the rest of the day starts, that routine disappears too. Small structures matter more than they seem when the pharmacological support is gone.

What your prescriber would normally discuss before you stop

A supervised discontinuation typically involves reviewing whether stopping is the right call at all, what has changed, and what support is in place afterward. NHS England's guidance on weight management injections frames these medicines as part of a broader programme of lifestyle change, not a standalone fix, stopping is most sustainable when diet and activity habits have already shifted.

Prescribers also consider whether a pause is more appropriate than a full stop. If cost, supply or a planned procedure is driving the question, there are often alternative approaches. For anyone wondering about what happens after a month off Wegovy, the evidence suggests noticeable changes but not an irreversible reset. Resuming treatment, with prescriber oversight, is possible.

If stopping is the right decision, some prescribers prefer a step-down approach: reducing to a lower maintenance dose for a period before discontinuing entirely. This is not universally recommended, and the SmPC does not mandate a taper, but it may ease the transition for some patients. That is a clinical judgement made between you and your prescriber, not a rule to follow or ignore independently.

You can read more about semaglutide as a medicine, or explore Wegovy's full prescribing context, to understand how ongoing treatment decisions are made. If you are considering treatment for the first time or looking to restart after a break, finding a regulated UK provider is a reasonable first step. All weight-loss treatment options available through nume are outlined on the weight loss treatments overview.

If you have specific questions about your own situation or want a prescriber to review your history before making a decision, you can start a free consultation with our clinical team.